The antibody trastuzumab inhibits human epidermal growth factor receptor 2 (HER2/ErbB2) in HER2-positive breast cancer and was one of the first approved targeted therapies in the late 1990s[119]. This evidence concerns the gene ERBB2 and breast carcinoma.